Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Novartis Pharmaceuticals Corporation
EIR
•Novartis Pharmaceuticals Corporation•August 21, 2019

Novartis Pharmaceuticals Corporation – FDA EIR, Aug 21, 2019

Record Details

An FDA inspection of Novartis Pharmaceuticals Corp in Morris Plains, NJ, was conducted from August 13-21, 2019. This Level 1 inspection focused on the manufacturing operations of Kymriah (tisagenlecleucel), an autologous cell therapy product, under the regulatory framework of the Team Biologics FY’2019 work plan and Compliance Program 7345.848(F) for Biological Drug Products. The inspection resulted in an FDA Form 483, detailing several significant observations. Key issues included inadequate stability data for Kymriah, with some product lots failing cell viability tests at 6 and 9 months, indicating potential shelf-life instability. Novartis was cited for not adequately establishing the stability profile for a specific manufacturing version of Kymriah and for failing to assess product lots that did not meet cell viability criteria, contrary to their own procedures. Furthermore, an investigation into a cell viability out-of-specification trend lacked a comprehensive corrective and preventative action (CAPA) plan. Other observations highlighted a lack of data supporting the qualification of critical raw materials, disinfectant agents failing validation criteria, and deficiencies in aseptic processing. The implemented CAPAs for cell viability failures were deemed ineffective, and the firm exhibited systemic weaknesses in CAPA management, including a failure to establish timely implementation, evaluate effectiveness, and properly close actions. Additionally, the company did not consistently identify out-of-specification stability trends, and its periodic review procedures lacked detailed CAPA assessments. Novartis management committed to providing a formal response to the FDA within 15 business days to address these findings.

Company
Novartis Pharmaceuticals Corporation
Inspection date
August 21, 2019
Product type
biologics
Office
Center for Biologics Evaluation and Research
People
  • Susan M. Jackson (investigator)
  • Colleen Hoyt
  • Kimberly L. Schultz (investigator)
  • Jacqueline M. Diaz Albertini (investigator)
View Company Profile

ID · 43fb0c26-6023-4fdb-a1bf-b32b89a06cda

Violation Codes5
21 CFR 211.113(b)21 CFR 211.110(a)21 CFR 820.10021 CFR 211.19221 CFR 211.180(e)(2)

Full citation text and observation details available on the Dashboard.

Other documents for Novartis Pharmaceuticals Corporation
  • 483 - 2026-02-06February 6, 2026
  • 483 - 2024-08-08August 8, 2024
  • UNTITLED_LETTER - 2023-08-08August 8, 2023
  • 483 - 2022-12-09December 9, 2022
  • 483 - 2019-08-21August 21, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Novartis Pharmaceuticals Corporation
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.